JP2004508380A - １７−β−（Ｎ−ｔｅｒ−ブチルカルバモイル）−４−アザ−５−α−アンドロスト−１−エン−３−オンの新規の多形体及びその調製方法 - Google Patents

１７−β−（Ｎ−ｔｅｒ−ブチルカルバモイル）−４−アザ−５−α−アンドロスト−１−エン−３−オンの新規の多形体及びその調製方法 Download PDF

Info

Publication number
JP2004508380A
JP2004508380A JP2002525173A JP2002525173A JP2004508380A JP 2004508380 A JP2004508380 A JP 2004508380A JP 2002525173 A JP2002525173 A JP 2002525173A JP 2002525173 A JP2002525173 A JP 2002525173A JP 2004508380 A JP2004508380 A JP 2004508380A
Authority
JP
Japan
Prior art keywords
androst
aza
butylcarbamoyl
tert
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002525173A
Other languages
English (en)
Japanese (ja)
Inventor
レディー、エム・サティアナラヤナ
ラジャン、エス・ティー
ラオ、エム・ブイ・エヌ・ブラーメシュワラ
ビアス、ケー
レディー、エス・ビシュヌバルダーナ
レカー、ケー・シャシ
Original Assignee
ドクター・レディーズ・ラボラトリーズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドクター・レディーズ・ラボラトリーズ・リミテッド filed Critical ドクター・レディーズ・ラボラトリーズ・リミテッド
Publication of JP2004508380A publication Critical patent/JP2004508380A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002525173A 2000-09-07 2001-06-19 １７−β−（Ｎ−ｔｅｒ−ブチルカルバモイル）−４−アザ−５−α−アンドロスト−１−エン−３−オンの新規の多形体及びその調製方法 Withdrawn JP2004508380A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN737DE2000 2000-09-07
PCT/US2001/019546 WO2002020553A1 (en) 2000-09-07 2001-06-19 NOVEL POLYMORPHIC FORM OF 17-β-(N-TER.BUTYL CARBAMOYL)-4-AZA-5-α-ANDROST-1-EN-3-ONE AND A PROCESS FOR PREPARING IT

Publications (1)

Publication Number Publication Date
JP2004508380A true JP2004508380A (ja) 2004-03-18

Family

ID=11097081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002525173A Withdrawn JP2004508380A (ja) 2000-09-07 2001-06-19 １７−β−（Ｎ−ｔｅｒ−ブチルカルバモイル）−４−アザ−５−α−アンドロスト−１−エン−３−オンの新規の多形体及びその調製方法

Country Status (12)

Country Link
EP (1) EP1322663A1 (de)
JP (1) JP2004508380A (de)
AU (1) AU6991101A (de)
BR (1) BR0113732A (de)
CA (1) CA2422159A1 (de)
HU (1) HUP0300937A3 (de)
IL (1) IL154785A0 (de)
NO (1) NO20031045L (de)
NZ (1) NZ525116A (de)
PL (1) PL361014A1 (de)
WO (1) WO2002020553A1 (de)
ZA (1) ZA200302554B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2206065B1 (es) * 2002-10-31 2005-08-16 Ragactives, S.L. Procedimiento para la obtencion de la forma polimorfica i de finasterida.
ATE406376T1 (de) * 2003-07-03 2008-09-15 Cipla Ltd Verfahren zur herstellung von finasterid form i
CN1294913C (zh) * 2004-12-23 2007-01-17 鲁南制药集团股份有限公司 含有非那雄胺与环糊精或其衍生物的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225100A (en) * 1987-06-29 1991-09-25 Merck & Co Inc Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US5021575A (en) * 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids
US5091534A (en) * 1990-08-27 1992-02-25 Merck & Co., Inc. Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes

Also Published As

Publication number Publication date
ZA200302554B (en) 2004-02-19
NO20031045L (no) 2003-04-29
EP1322663A1 (de) 2003-07-02
NZ525116A (en) 2004-11-26
BR0113732A (pt) 2003-07-29
IL154785A0 (en) 2003-10-31
WO2002020553A1 (en) 2002-03-14
AU6991101A (en) 2002-03-22
HUP0300937A2 (en) 2007-02-28
NO20031045D0 (no) 2003-03-06
PL361014A1 (en) 2004-09-20
HUP0300937A3 (en) 2007-10-29
CA2422159A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
EP1602662B1 (de) Verfahren zur gewinnung von 17alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dion
EP0307134B1 (de) Verfahren zur Herstellung von Androsta-1,4-dien-3,17-dion-methylen-Derivaten
JPH089610B2 (ja) 置換イソフラボン誘導体の改良された製造方法
US5116983A (en) Dehydrogenation process intermediates
CA2891751A1 (en) Solid and crystalline dutasteride and processes for preparation thereof
WO2007073937A2 (en) Process for preparing crystalline forms of orlistat
JP2004508380A (ja) １７−β−（Ｎ−ｔｅｒ−ブチルカルバモイル）−４−アザ−５−α−アンドロスト−１−エン−３−オンの新規の多形体及びその調製方法
TWI354675B (en) Process for preparing aromatase inhibitors
US7501515B2 (en) Polymorphic form of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-1-en-3-one
EP1790653A2 (de) Neue polymorphe Form von 17-beta-(n-ter.butyl carbomyol)-4-aza-5- alpha-androst-1-en-3-one und ein Verfahren zu ihrer Herstellung
AU2001269911A1 (en) Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it
US7795435B2 (en) Process for obtaining the polymorphic form I of finasteride
CN114790161B (zh) 4-甲氧基羰基乙基-3-甲基-2-吡咯醛的合成方法及其中间体
JPH10506411A (ja) （２２ＲＳ）−Ｎ−（１，１，１−トリフルオロ−２−フェニルプロプ−２−イル）−３−オキソ−４−アザ−５α−アンドロスト−１−エン−１７β−カルボキサミド
JPH051053A (ja) ６−（３−ジメチルアミノプロピオニル）フオルスコリンの新規製造法
US20060247452A1 (en) Method for obtaining 17sg(a)-acetoxy-11$g(b)-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione
JPS6325000B2 (de)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061020

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20061020

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20061020

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20080902